Change in Serum Hepatitis B Surface Antigen Level and Its Clinical Significance in Treatment-naive, Hepatitis B e Antigen-positive Patients Receiving Entecavir
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Kim, Ji Hoon | - |
dc.contributor.author | Lee, Young Sun | - |
dc.contributor.author | Lee, Hyun Jung | - |
dc.contributor.author | Yoon, Eileen | - |
dc.contributor.author | Jung, Eun Suk | - |
dc.contributor.author | Hong, Seung Kwon | - |
dc.contributor.author | Joo, Moon Kyung | - |
dc.contributor.author | Yeon, Jong Eun | - |
dc.contributor.author | Park, Jong Jae | - |
dc.contributor.author | Kim, Jae Seon | - |
dc.contributor.author | Bak, Young-Tae | - |
dc.contributor.author | Byun, Kwan Soo | - |
dc.date.available | 2020-11-03T05:44:32Z | - |
dc.date.issued | 2010-10 | - |
dc.identifier.issn | 0192-0790 | - |
dc.identifier.issn | 1539-2031 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/14447 | - |
dc.description.abstract | Background/Aim We investigated changes in hepatitis B surface antigen (HBsAg) level and its correlation with clinical outcomes in treatment-naive chronic hepatitis B (CHB) patients undergoing entecavir therapy. Patients and Methods Among 51 hepatitis B e antigen (HBeAg)-positive treatment-naive CHB patients receiving entecavir for more than 1 year, 28 were enrolled. HBsAg levels were measured at baseline, 6 months, and 12 months after treatment using the Architect HBsAg QT assay (Abbott, dynamic; range: 0.05 to 125,000 IU/mL). Serum alanine aminotransferase, HBeAg, anti-HBe, and hepatitis B virus (HBV) DNA (Cobas Taqman: low detection limit 1.84 log10 copies/mL) were measured at baseline and every 3 months. The HBsAg response was defined as an HBsAg level that decreased more than 1 log10 IU/mL from baseline level at 12 months after entecavir treatment. Results Twenty-eight patients were treated for a median period of 21 months (range: 18 to 24 mo). Serum HBsAg level showed a mean of 4.0, 3.7, and 3.6 log10 IU/mL at pretreatment, 6, and 12 months, respectively, and declined significantly (P<0.001). Serum HBV DNA level showed a mean of 8.1, 3.1, and 2.4 log10 copies/mL at pretreatment, 6, and 12 months, respectively, and declined significantly (P<0.001). The decline in HBsAg level was significantly correlated with that of the HBV DNA level at 12 months from baseline (γ=0.391, P=0.044). Five patients showed an HBsAg response, and cumulative incidence of HBeAg loss at 1 year after entecavir treatment was 80% versus 30% in patients with an HBsAg response and those without, respectively (P=0.034). Conclusions Monitoring changes in quantitative HBsAg level could be a useful parameter for assessing the response to entecavir therapy in HBeAg-positive treatment-naive CHB patients. | - |
dc.format.extent | 5 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | Lippincott Williams & Wilkins Ltd. | - |
dc.title | Change in Serum Hepatitis B Surface Antigen Level and Its Clinical Significance in Treatment-naive, Hepatitis B e Antigen-positive Patients Receiving Entecavir | - |
dc.type | Article | - |
dc.publisher.location | 미국 | - |
dc.identifier.doi | 10.1097/MCG.0b013e3181d52946 | - |
dc.identifier.scopusid | 2-s2.0-77957596906 | - |
dc.identifier.wosid | 000281833800009 | - |
dc.identifier.bibliographicCitation | Journal of Clinical Gastroenterology, v.44, no.9, pp 653 - 657 | - |
dc.citation.title | Journal of Clinical Gastroenterology | - |
dc.citation.volume | 44 | - |
dc.citation.number | 9 | - |
dc.citation.startPage | 653 | - |
dc.citation.endPage | 657 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | SPONTANEOUS HBSAG SEROCLEARANCE | - |
dc.subject.keywordPlus | CLOSED CIRCULAR DNA | - |
dc.subject.keywordPlus | PEGINTERFERON ALPHA-2A | - |
dc.subject.keywordPlus | SUSTAINED RESPONSE | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | HBEAG | - |
dc.subject.keywordPlus | LAMIVUDINE | - |
dc.subject.keywordPlus | REDUCTION | - |
dc.subject.keywordPlus | QUANTITATION | - |
dc.subject.keywordPlus | PREDICTOR | - |
dc.subject.keywordAuthor | hepatitis B surface antigen | - |
dc.subject.keywordAuthor | chronic hepatitis B | - |
dc.subject.keywordAuthor | treatment-naive | - |
dc.subject.keywordAuthor | hepatitis B e antigen positive | - |
dc.subject.keywordAuthor | entecavir | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.